European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Dec 2021
Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project.
Proton-pump inhibitors (PPIs) are among the most frequently prescribed drugs, but they are being overprescribed. ⋯ There is a high inappropriate indication for PPIs in patients admitted to the gastroenterology department. The application of a patient-centered deprescribing algorithm is a safe and effective strategy to reduce their inappropriate consumption in the medium term.
-
Eur. J. Clin. Pharmacol. · Apr 2021
The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.
To assess, with all available trial information, whether the assessment of the PRECIS-2 nine domains could provide a clear distinction between medicine masked pragmatic randomized controlled trials (pRCTs) and open-label pRCTs. ⋯ The PRECIS-2 tool seems not to be sensitive enough to clearly discriminate between medicine masked pRCTs and open-label pRCTs. When conducting systematic reviews, it is suggested that the PRECIS-2 tool should not be used to support placing masked trials in the pragmatic side of the explanatory/pragmatic continuum.
-
Eur. J. Clin. Pharmacol. · Feb 2021
Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Although more practical for use, the impact of ferric carboxymaltose (FCM) on the hospital budget is considerable, and intravenous iron sucrose complex (ISC) represents a cost-saving alternative for the management of iron deficiency anemia in patients during hospitalization. The Drug Committee decided to reserve FCM for day hospitalizations and contraindications to ISC, especially allergy. ISC was available for prescription for all other situations. ⋯ Our intervention to lower the impact of intravenous iron therapy on the hospital budget was effective.